ClinicalTrials.gg
RecruitingNCT07239336Updated Aug 14, 2026

Study of DONQ52 in Active Celiac Disease

A Phase 2 interventional study of Placebo DONQ52 and Simulated Inadvertent Gluten Exposure (SIGE) capsule in Celiac Disease, sponsored by Chugai Pharmaceutical. Recruiting at 74 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Chugai Pharmaceutical (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.

Planned enrollment
22nd of 68
92 · median 46
Started
2025
with 4 others
Phase 2
21 of 103
1 open now
Primary completion
2027-06
later than 9 of 19 live
Registered
102nd of 103
by date
Lead sponsor
3 of 103
Chugai Pharmaceutical

Among the 103 studies in Celiac Disease with a site in United States, this one is the 22nd largest by planned enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2025, is one of 21 in phase 2, reaches primary completion later than 9 of the 19 other live ones, and was the 102nd registered.

Celiac Disease

352 studies on the registry are indexed under Celiac Disease; 77 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Celiac Disease with a site in United States, or all of them as a file.
02

Study summary

The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.

03

Conditions studied

  • Celiac Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 18 to 40 (kg/m2) at screening.
  • Willingness to ingest a gluten-free product and Simulated Inadvertent Gluten Exposure (SIGE) products as per the study protocol.
  • History of medically diagnosed, and adequately documented (i.e., included in the participant's medical records), CeD
  • Attempting a GFD for at least 12 months prior to the screening visit.

    - The participants should be instructed not to alter dietary habits including a GFD during the study period.

  • Valid results from central testing of blood documenting a positive result for the HLA DQ2.5 genotype (HLA-DQA1*05 and HLA-DQB1*02) (homozygous or heterozygous).
  • Experienced at least 2 gluten-related symptom events (i.e., 2 different gluten-related symptoms which are diarrhea, abdominal pain, bloating, nausea, tiredness or 1 gluten-related symptom occurred twice) within a month before the screening.
  • Willingness to undergo 2 on-study upper gastrointestinal endoscopies with duodenal .
  • Presence of ongoing duodenal mucosal damage defined as Vh:Cd of 2.5 or less

Exclusion criteria

Exclusion Criteria:

  • Participants with documented history (i.e., included in the participant's medical records) of medically diagnosed Celiac Disease (RCD) or suspected RCD by the investigator.
  • History of IgE-mediated reactions to wheat, barley, rye, or other ingredients in gluten-free and SIGE products used in this study (i.e., methylcellulose, and gelatin).
  • History of cancer, including hematological and solid tumors, within 5 years prior to the screening visit, or history of T cell lymphoma or B cell lymphoma ever.
  • History of reactions including anaphylaxis to a biological medical product or any of the .
  • Participants who carry the HLA-DQ8 (HLA-DQA1*03 and DQB1*0302) genotype (homozygous or heterozygous).
  • Any other chronic, active gastrointestinal disease (e.g., inflammatory bowel disease, microscopic colitis, eosinophilic esophagitis, peptic ulcer, gastroesophageal reflux disease, functional dyspepsia, or irritable bowel syndrome) that might in the investigator's opinion, interfere with the assessment of GI symptoms or small intestinal histology.
  • Helicobacter pylori tests that indicate current infection.
  • Positive either (HIV) antigen or antibody test at screening.
  • Positive surface antigen (HBsAg) test or total hepatitis B core (HBc) antibody test at screening.
  • Positive virus (HCV) antibody test at screening, except in participants who have negative results for HCV ribonucleic acid (RNA) test at screening.
  • Positive for QuantiFERON-TB Gold test at screening that indicates active tuberculosis (TB) at screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
92 participants (estimated)

Study arms

  • Placebo comparator
    Placebo + SIGE Gluten capsule

    Placebo subcutaneous (SC) injection as per protocol + SIGE Gluten capsule orally

    Drug: Placebo DONQ52 · Dietary Supplement: Simulated Inadvertent Gluten Exposure (SIGE) capsule

  • Experimental
    DONQ52 + SIGE Gluten capsule

    DONQ52 subcutaneous (SC) injection as per protocol + SIGE Gluten capsule orally

    Drug: DONQ52 · Dietary Supplement: Simulated Inadvertent Gluten Exposure (SIGE) capsule

Interventions

  • DrugPlacebo DONQ52

    Placebo DONQ52 subcutaneous injection

  • Dietary supplementSimulated Inadvertent Gluten Exposure (SIGE) capsule

    SIGE gluten capsules orally

  • DrugDONQ52

    DONQ52 subcutaneous injection

  • Dietary supplementSimulated Inadvertent Gluten Exposure (SIGE) capsule

    SIGE gluten capsules orally

06

What researchers measure

Primary outcomes

  1. Change in Villous Height to Crypt Depth Ratio (Vh:Cd)

    The Vh:Cd ratio represents mucosal architectural changes and a lower Vh:Cd ratio indicates more severe intestinal injury characterized by a flattening of the mucosa. The difference in the adjusted mean change from baseline (Run-in) to Week 27 in Vh:Cd between DONQ52 and placebo groups will be estimated using the analysis of covariance (ANCOVA) method. A negative change from baseline indicates worsening disease.

    Time frame: Baseline to Week 27

Secondary outcomes

  1. Change in Average of total score of Celiac Disease Symptom Diary (CDSD) Gastrointestinal (GI) domain (abdominal pain, diarrhea, nausea, and bloating) calculated as two-week average.

    CDSD symptom severity score is an average of the daily symptom severity scores during the week. The daily symptom severity score is the average of the severity score for diarrhea, abdominal pain, bloating, nausea, and tiredness ranging from 0 to 4. Symptom severity is evaluated using 5-point Likert-type scales (none, mild, moderate, severe, and very severe). Higher scores indicate more severe symptoms. Results are reported as mean change from baseline at Week 13-14 and Week 25-26. A negative change from baseline indicates improvement.

    Time frame: Baseline to Week 27

  2. Change in Average of the total score of non-stool GI symptoms (abdominal pain, nausea, and bloating) calculated as two-week average.

    CDSD GI symptom severity score is an average of the daily non-stool GI symptom severity scores during the week. The daily non-stool GI symptom severity score is the average of the severity score for abdominal pain, nausea, and bloating, ranging from 0 to 4. Symptom severity is evaluated using 5-point Likert-type scales (none, mild, moderate, severe, and very severe). Higher scores indicate more severe symptoms. Results are reported as mean change from baseline at Week 13-14 and Week 25-26. A negative change from baseline indicates improvement.

    Time frame: Baseline to Week 27

  3. Change in Average of diarrhea frequency score as assessed by CDSD frequency supplement calculated as two-week average.

    Diarrhea frequency score assessed by CDSD frequency supplement is an average of the daily diarrhea frequency score during the week. Results are reported as mean change from baseline at Week 13-14 and Week 25-26. A negative change from baseline indicates improvement.

    Time frame: Baseline to Week 27

  4. Relationship between the total score of CDSD GI domain and Patient Global Impression of Severity (PGI-S) or Patient Global Impression of Change (PGI-C).

    The PGI-S is a Patient-Reported Outcome (PRO) measure assessing participant's impression of overall severity of disease symptoms. The PGI-S consists of single-item which asks participant's disease severity over the past 7 days and 14 days. It is rated on a 5-point scale from None to Very Severe. This PGI-S has been specifically modified to focus on celiac disease symptoms (i.e., abdominal pain, bloating, diarrhea, and nausea), adapting the standard PGI-S framework to be celiac disease-specific. The PGI-C is a PRO measure assessing participant's impression of the overall change in disease symptoms. The PGI-C consists of single-item which asks the change of participant's clinical status since the start of the study. It is rated on a 7-point scale from Very Much Improved to Very Much Worse. This PGI-C has been specifically modified to focus on celiac disease symptoms (i.e., CDSD GI items), adapting the standard PGI-C framework to be celiac disease-specific.

    Time frame: Baseline to 47 weeks

  5. Incidence and severity of adverse events (AEs) and their causal relationship to the investigational medicinal products (IMPs).

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a markedly abnormal physical examination finding, vital sign value, laboratory test value), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug.The investigator clinically judges whether an AE was caused by the IMP. This assessment of causality, often categorized as "related" or "not related," is a distinct step performed after an event has been identified and recorded as an AE.

    Time frame: Baseline to 47 weeks

  6. Serum DONQ52 concentration.

    Time frame: Day1 to 47 weeks

  7. Prevalence of anti-drug antibodies (ADAs) to DONQ52.

    Time frame: Day1 to 47 weeks

  8. Incidence of anti-drug antibodies (ADAs) to DONQ52.

    Time frame: Day1 to 47 weeks

07

Study locations

74 of 74 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform. For further details on Chugai's Data Sharing Policy and how to request access to related clinical study documents, see here (www.chugai-pharm.co.jp/english/profile/rd/ctds_request.html).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.

Of 24 phase 2 interventional studies under Celiac Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's planned 17 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Nov 20, 2025
StartActual
Dec 16, 2025
Primary completionEst.
Jun 15, 2027
CompletionEst.
Dec 15, 2027
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07239336
Responsible party
Sponsor
First posted
Nov 20, 2025
Start date
Dec 16, 2025
Primary completion
Jun 15, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

Clinical trials information
Contact
clinical-trials@chugai-pharm.co.jp
only use Email
Chugai Pharmaceutical Co., Ltd.
study director · clinical-trials@chugai-pharm.co.jp

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion